Menu
Search
|

Menu

Close
X

Kazia Therapeutics Ltd KZIA.OQ (NASDAQ Stock Exchange Capital Market)

3.33 USD
-0.28 (-7.88%)
As of 1:30 AM IST
chart
Previous Close 3.62
Open 3.58
Volume 2,153
3m Avg Volume 5,167
Today’s High 3.64
Today’s Low 3.33
52 Week High 6.64
52 Week Low 2.28
Shares Outstanding (mil) 4.83
Market Capitalization (mil) 15.39
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, AUD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (AUD)
FY18
0.009
FY17
-0.227
FY16
-0.282
FY15
-0.290
*Note: Units in Millions of Australian Dollars
**Note: Units in Australian Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
79.63
5.73
Price to Book (MRQ)
vs sector
0.18
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-33.03
14.61
Return on Equity (TTM)
vs sector
-36.01
16.34

EXECUTIVE LEADERSHIP

Iain Ross
Non-Executive Chairman of the Board, Since 2017
Salary: --
Bonus: --
James Garner
Chief Executive Officer, Executive Director, Since 2016
Salary: --
Bonus: --
Bryce Carmine
Non-Executive Deputy Chairman of the Board, Since 2016
Salary: --
Bonus: --
Gordon Hirsch
Chief Medical Officer, Since 2016
Salary: --
Bonus: --
Lilischkis Kimberley
Clinical & Regulatory Affairs Manager, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

L 5 20 George St
SYDNEY   NSW   2077

Phone: +612.98780088

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.

SPONSORED STORIES